证券代码：600161 证券简称：天坛生物 公告编号：2025-037 北京天坛生物制品股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 （一）股东会召开的时间：2025 年 8 月 20 日 （二）股东会召开的地点：北京市朝阳区双桥路乙 2 号院会议室 （三）出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 1,355 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 1,050,253,152 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总 | 53.11 | | 数的比例（%） | | 1、议案名称：《关于变更法定代表人的议案》 审议结果：通过 表决情况： （四）表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次会议由董事会召集，董事长杨汇川先生主持，会议采用现场投票与网络投票 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Shenzhou Cell, which has a high PE ratio compared to its industry peers [1][2] - As of August 19, Shenzhou Cell's stock closed at 71.4 yuan, down 2.19%, with a rolling PE ratio of 313.20 and a total market capitalization of 31.797 billion yuan [1] - The average PE ratio for the biopharmaceutical industry is 73.41, with a median of 45.28, placing Shenzhou Cell at the 72nd position among its peers [1][2] Group 2 - As of the first quarter of 2025, 17 institutions hold shares in Shenzhou Cell, with a total of 2.7733 million shares valued at 166 million yuan [1] - The company specializes in the research and commercialization of biopharmaceutical products for various diseases, including cancer and autoimmune diseases, with key products such as SCT800 and SCT400 [1] - In the latest financial report for the first quarter of 2025, Shenzhou Cell reported a revenue of 520 million yuan, a year-on-year decrease of 15.15%, and a net profit of 63.768 million yuan, down 14.06%, with a gross margin of 94.88% [1]

Core Viewpoint - TianTan Biological (600161) is actively developing its international market presence and aims to become a globally influential blood product enterprise, aligning with China's "Belt and Road" initiative [1][2]. Group 1: International Expansion - The company does not have any production bases overseas [2]. - It is steadily advancing the international market development and registration preparations for new products [2]. - The focus is on obtaining international certifications and registrations for key products [2].

Core Viewpoint - The approval process for seven products from Kunming Blood Products has progressed to the comprehensive review and final approval stage, raising questions about the timeline for production post-approval [1] Group 1: Company Updates - Tian Tan Bio (600161.SH) confirmed that the Yunnan project has completed the on-site verification of major product registrations and GMP compliance inspections [1] - The company is currently addressing inspection deficiencies and is proceeding with the review of the registered products according to the registration progress [1] - Tian Tan Bio plans to actively communicate with government departments to expedite the transfer of production sites for major products related to the Shanghai Yunnan project [1]

Group 1 - The company has not launched any new products so far this year [2] - Two new products, "subcutaneous injection of human immunoglobulin" and "recombinant human coagulation factor VIIa for injection," have completed clinical trials and submitted for market approval [2]

Group 1 - The company TianTan Bio (600161.SH) has completed clinical trials for its subcutaneous human immunoglobulin product and plans to submit a marketing authorization application by December 2024 [2] - The product features a protein concentration increased to 20% and utilizes a sugar-free amino acid formulation, transitioning the administration route from intravenous to subcutaneous injection, which offers more effective, comfortable, convenient, and economical treatment options [2] - Upon approval, the product is expected to provide patients with a new treatment choice, enhancing the company's product portfolio [2]

Group 1 - The core business of the company is the research, production, and sales of blood products, not involving vaccine business [1] - The company operates in the blood products industry [1] - The company has three main categories of products on the market: human albumin, human immunoglobulin, and human coagulation factors, along with recombinant coagulation factor products [1]

Group 1 - The company does not engage in vaccine development, specifically for HIV vaccines [2] - The main business of the company is the research, production, and sales of blood products [2] - The company operates in the blood products industry, with key products including human albumin, human immunoglobulin, and human coagulation factors, as well as recombinant coagulation factor products [2]

Group 1 - The company currently has 22 plasma collection stations under construction [2] - The distribution of these stations includes 11 in Lanzhou, 9 in Shanghai, and 2 in Wuhan [2] - The company is actively communicating with industry regulatory authorities to promote the construction and operational application of its plasma stations [2]

每经AI快讯，有投资者在投资者互动平台提问：请问公司目前在云南新设单采浆站情况是怎样的？已 经取得多少个县级审批同意和市级同意许可？ 天坛生物（600161.SH）8月14日在投资者互动平台表示，截至目前，公司在云南省已有5家单采血浆站 执业，仍有8家浆站筹建中。 （文章来源：每日经济新闻） ...